RegulatoryOfficial

European Commission authorises Biocon Biologics' Pebrilzo (pertuzumab) in the EU

🇪🇺 European Commission (Union Register) · Fri 13 Nov 2026

Commission Decision (2026) 8284 of 13 November 2026 grants a new marketing authorisation for pertuzumab product Pebrilzo, held by Biocon Biologics Ireland Limited.

The European Commission has granted a marketing authorisation to Pebrilzo, a pertuzumab medicine held by Biocon Biologics Ireland Limited. The decision is recorded in the Union Register of medicinal products for human use.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: European Commission (Union Register) ↗

Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.